ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 61 filers reported holding ADC THERAPEUTICS SA in Q2 2021. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $192,481 | -12.6% | 89,526 | -20.7% | 0.00% | – |
| Q1 2023 | $220,167 | -27.1% | 112,906 | +43.5% | 0.00% | – |
| Q4 2022 | $302,000 | -18.8% | 78,670 | +2.0% | 0.00% | – |
| Q3 2022 | $372,000 | -41.5% | 77,103 | -3.6% | 0.00% | – |
| Q2 2022 | $636,000 | -42.3% | 79,976 | +6.6% | 0.00% | – |
| Q1 2022 | $1,102,000 | -17.8% | 75,030 | +13.1% | 0.00% | – |
| Q4 2021 | $1,340,000 | -28.3% | 66,352 | -3.6% | 0.00% | -100.0% |
| Q3 2021 | $1,869,000 | +14.3% | 68,815 | +2.7% | 0.00% | 0.0% |
| Q2 2021 | $1,635,000 | +9.0% | 67,034 | +9.1% | 0.00% | – |
| Q1 2021 | $1,500,000 | -36.8% | 61,419 | -17.1% | 0.00% | -100.0% |
| Q4 2020 | $2,372,000 | +28.6% | 74,102 | +32.5% | 0.00% | 0.0% |
| Q3 2020 | $1,845,000 | -39.1% | 55,925 | -13.6% | 0.00% | 0.0% |
| Q2 2020 | $3,029,000 | – | 64,710 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $4,555,066 | 2.69% |
| Blue Owl Capital Holdings LP | 733,568 | $2,816,901 | 1.20% |
| Redmile Group, LLC | 7,590,849 | $29,148,860 | 1.19% |
| AlphaCentric Advisors LLC | 297,500 | $1,142,400 | 1.13% |
| Prosight Management, LP | 463,310 | $1,779,110 | 0.97% |
| GCM Grosvenor Holdings, LLC | 735,471 | $2,824,209 | 0.72% |
| Indie Asset Partners, LLC | 93,839 | $360,342 | 0.40% |
| XTX Topco Ltd | 197,635 | $758,918 | 0.16% |
| Eventide Asset Management | 1,879,959 | $7,219,043 | 0.14% |
| Nantahala Capital Management | 243,290 | $934,234 | 0.06% |